0001437749-23-028701.txt : 20231023 0001437749-23-028701.hdr.sgml : 20231023 20231023060605 ACCESSION NUMBER: 0001437749-23-028701 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231020 FILED AS OF DATE: 20231023 DATE AS OF CHANGE: 20231023 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TATE JEFFREY CENTRAL INDEX KEY: 0001499075 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39780 FILM NUMBER: 231338438 MAIL ADDRESS: STREET 1: C/O CTD HOLDINGS, INC. STREET 2: 27317 NW 78TH AVENUE CITY: HIGH SPRINGS STATE: FL ZIP: 32643 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyclo Therapeutics, Inc. CENTRAL INDEX KEY: 0000922247 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 593029743 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6714 NW 16TH STREET, SUITE B CITY: GAINESVILLE STATE: FL ZIP: 32653 BUSINESS PHONE: 386-418-8060 MAIL ADDRESS: STREET 1: PO BOX 1180 CITY: ALACHUA STATE: FL ZIP: 32616-1180 FORMER COMPANY: FORMER CONFORMED NAME: CTD HOLDINGS INC DATE OF NAME CHANGE: 20000913 FORMER COMPANY: FORMER CONFORMED NAME: CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC DATE OF NAME CHANGE: 19941012 4 1 rdgdoc.xml FORM 4 X0508 4 2023-10-20 0000922247 Cyclo Therapeutics, Inc. CYTH 0001499075 TATE JEFFREY C/O CYCLO THERAPEUTICS, INC. 6714 NW 16TH STREET, SUITE B GAINESVILLE FL 32163 1 1 Chief Operating Officer 0 Common Stock 2023-10-20 4 X 0 29941 0.71 A 92042 D Warrant to Purchase Common Stock 0.71 2023-10-20 4 X 0 29941 0.125 D 2023-04-20 2030-04-20 Common Stock 29941 0 D Warrant to Purchase Common Stock 0.95 2023-10-20 4 P 0 32935 A 2023-10-20 2027-10-20 Common Stock 32935 32935 D The Reporting Person exercised vested Warrants (the "Original Warrants") to purchase 29,941 shares of the Issuer's common stock pursuant to a Securities Purchase Agreement dated October 20, 2023 ("Closing Date"). The Reporting Person exercised his Original Warrant in full on or prior to the Closing Date in consideration of the receipt of new warrants with an exercise price equal to $0.95 per share, to purchase 110% of the shares of the Issuer's common stock covered under the Original Warrants. /s/ Jeffrey Tate 2023-10-23